Updated Jul 16, 2026
Deykin Aaron has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $14K.
Aaron Deykin is a corporate insider serving as Chief Medical Officer of Upstream Bio, Inc., a clinical-stage biotechnology company developing verekitug, a TSLP receptor antagonist, to treat inflammatory diseases. The SEC filing for UPB (CIK 0002031693) lists him as Chief Medical Officer, with the most recent report dated 2026-01-06 and no reported stock purchases or sales.
| Role | Insider |
|---|---|
| Notability | 40/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-17 | UPB | Upstream Bio, Inc. | S — Open-market sale | 895 | $6.10 | $5K |
| 2026-03-17 | UPB | Upstream Bio, Inc. | S — Open-market sale | 894 | $9.29 | $8K |
| 2026-01-06 | UPB | Upstream Bio, Inc. | A — Grant or award | 32.0K | $0.00 |
Aaron Deykin is a corporate insider serving as Chief Medical Officer of Upstream Bio, Inc., a clinical-stage biotechnology company developing verekitug, a TSLP receptor antagonist, to treat inflammatory diseases. The SEC filing for UPB (CIK 0002031693) lists him as Chief Medical Officer, with the most recent report dated 2026-01-06 and no reported stock purchases or sales.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($14K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Deykin Aaron profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.